FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Portfolio Pulse from
The FDA has approved Amgen's LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for treating KRAS G12C-mutated metastatic colorectal cancer. This combination has shown to more than double progression-free survival compared to the standard of care.
January 17, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen received FDA approval for LUMAKRAS® in combination with Vectibix® for KRAS G12C-mutated metastatic colorectal cancer, potentially boosting its oncology portfolio.
The FDA approval of LUMAKRAS® in combination with Vectibix® is a significant milestone for Amgen, as it enhances their oncology portfolio and offers a new treatment option for a specific cancer mutation. This approval is likely to positively impact Amgen's stock price in the short term due to the potential increase in market share and revenue from this new treatment option.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100